N-Methyl-N-ethyltryptamine (MET) is the quiet middle child of the dialkyl tryptamine family -- structurally positioned exactly between DMT (dimethyl) and DET (diethyl), sharing the same basic scaffold as the most famous psychedelic molecule on earth but differing by exactly one carbon. That single carbon, extending one of DMT's methyl groups into an ethyl, changes more than you would expect. Like DMT, MET is primarily active when smoked or insufflated, with oral activity that is marginal at best without MAOI co-administration. Unlike DMT, the experience is consistently described as gentler, more spacious, and less overwhelming -- a quality that has earned it comparisons to "DMT with the volume turned down" or "the introductory tryptamine."
Alexander Shulgin synthesized and documented MET in TiHKAL (1997), placing it in the asymmetric N-alkyl tryptamine series alongside MiPT, MPT, and others. Shulgin noted its psychedelic activity and its structural position as a logical intermediate, but MET did not achieve the notoriety of its symmetric siblings. DMT had decades of cultural mythology. DET had clinical research history. MET had a footnote in a book that relatively few people read cover to cover. It was not until the research chemical market of the 2000s and 2010s that MET found an audience -- and even then, it remained one of the more obscure members of an already niche chemical family.
What that audience discovered was something genuinely useful: a short-acting tryptamine psychedelic (15-45 minutes smoked, 3-5 hours insufflated or with oral MAOI potentiation) with vivid DMT-like visuals, a manageable headspace, and an emotional warmth that makes it more forgiving than DMT for people who find the flash-intensity of a DMT breakthrough overwhelming. The geometry is recognizably tryptamine -- fractal chrysanthemums, morphing patterns, crystalline structures -- but arrives with a softer hand. The cognitive alteration is moderate: thoughts become associative and expansive without the complete identity dissolution that DMT can produce at equivalent visual intensity.
MET's obscurity is both its limitation and its charm. There is no extensive clinical literature, no cultural mythology, no religious organization using it as a sacrament. What there is, documented across scattered Reddit posts and harm reduction forums, is a compound that works well, demands less, and leaves people feeling that they experienced something real without being dismantled by it. For some users, that is exactly what they need.
Safety at a Glance
High Risk- Test Your Substance
- Smoked/vaporized: Threshold 5-10 mg | Light 10-20 mg | Common 20-40 mg | Strong 40-60+ mg
- Toxicity: Acute Physical Toxicity No formal human toxicological data exists for MET. Safety assessment relies on class membersh...
- Overdose risk: Can You Fatally Overdose on MET? Fatal overdose from MET's pharmacological action alone is extrem...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
oral
smoked
Duration
insufflated
Total: 2 hrs – 4 hrsoral
Total: 4 hrs – 6 hrssmoked
Total: 30 min – 1.3 hrsHow It Feels
The first thing you notice, within seconds of exhaling the vapor, is a rush of crystalline energy that floods upward from the chest into the head. The visual field brightens sharply -- colors saturate as if someone has adjusted the contrast on reality. A strong tingling spreads through the face and scalp, concentrated around the temples and behind the eyes, accompanied by a quickening pulse and a sense of alert, almost startled wakefulness. The air in the room seems to become denser and more luminous. If you have smoked DMT before, the onset will feel familiar, but there is an immediate difference in intensity: where DMT hits like a cannon, MET arrives more like a strong wave -- powerful, unmistakable, but not obliterating.
Over the next two to five minutes, the visual effects develop rapidly and reveal themselves as MET's signature. The geometry is unmistakably tryptamine: fractal chrysanthemum patterns, tessellating lattices, and morphing structures that ripple across surfaces and fill the closed-eye visual field with almost computational precision. Colors are vivid and full-spectrum, shifting through bright greens, electric blues, warm golds, and neon pinks with a fluidity that feels liquid. The visual quality has a crystalline sharpness to it -- precise angles, clean lines, and a mathematical beauty that feels less organic than psilocybin's flowing biomorphism. At moderate doses, these patterns overlay reality rather than replacing it; at higher doses, the external world begins to dissolve into pure geometry.
The peak arrives within five to fifteen minutes when smoked, holding for ten to twenty minutes before beginning a gradual descent. The headspace is the experience's most distinctive quality: it is present but proportionate. Thoughts become associative and lateral -- ideas connect in unexpected ways, and there is a sense of cognitive expansion -- but the core sense of self remains largely intact. You know who you are, where you are, and that you have taken a substance. This clarity at moderate visual intensity is what distinguishes MET from DMT: you can think about what you are seeing rather than merely being consumed by it. There is often a warm emotional undertone -- wonder, curiosity, a quiet appreciation for the strangeness of existence -- without the emotional extremes that heavier tryptamines produce.
The descent is clean and relatively swift. Over fifteen to thirty minutes, the geometry fades like a tide going out, leaving behind a residual brightness in the visual field and a pleasant sense of mental clarity. There is mild physical stimulation -- a buzzy alertness in the limbs -- that resolves within an hour. The total smoked duration of fifteen to forty-five minutes makes MET something rare in the psychedelic world: an experience that fits into an afternoon without colonizing the entire day. The afterglow is subtle but real: a quiet sharpness of perception, a lingering sense of visual enhancement, and a calm, clear headspace that can persist for several hours.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(19)
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Muscle cramp— Muscle cramps are sudden, involuntary, and often painful contractions of muscles that occur as a sid...
- Muscle relaxation— The experience of muscles throughout the body losing their rigidity and tension, becoming noticeably...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily heaviness— Perception of bodily heaviness is the subjective feeling that one's body has become dramatically hea...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vibrating vision— Vibrating vision is the subjective experience of the visual field rapidly oscillating or shaking due...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(21)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour replacement— A visual phenomenon in which the colors of objects or the entire visual field are statically replace...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Environmental patterning— A visual effect in which existing textures and surfaces — carpets, clouds, foliage, walls — spontane...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
- Visual exposure to inner mechanics of consciousness— A high-level hallucinatory state in which the observer perceives masses of complex, innately readabl...
Cognitive(20)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Focus suppression— Focus suppression is a diminished capacity to direct and sustain attention on a chosen target — a ta...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Language suppression— A diminished ability to formulate, comprehend, or articulate language, ranging from difficulty findi...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Mindfulness— Mindfulness in the substance context refers to a state of heightened present-moment awareness in whi...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(3)
- Machinescapes— Machinescapes are complex multisensory hallucinations involving the perception of enormous mechanica...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
MET is a partial agonist at serotonin 5-HT2A receptors -- the same primary mechanism shared by DMT, psilocin, LSD, and all classical tryptamine psychedelics. The asymmetric N-methyl-N-ethyl substitution pattern places it in a structural middle ground that appears to produce a binding profile subtly different from either DMT or DET. The subjective result -- visually rich but cognitively gentler than DMT -- suggests that the ethyl group modifies receptor interaction geometry in ways that favor perceptual effects over the profound ego-dissolving cognition that characterizes DMT at equivalent doses.
Oral Inactivity and MAO Metabolism
MET shares DMT's fundamental pharmacokinetic limitation: it is efficiently degraded by monoamine oxidase A (MAO-A) in the gut wall and liver. The single methyl-to-ethyl substitution provides only marginal improvement in MAO-A resistance -- enough to allow trace oral activity at very high doses, but not enough for reliable oral bioavailability at practical doses. This stands in contrast to DPT and DET, where the larger dialkyl groups reduce MAO-A affinity sufficiently for clear oral activity.
The practical consequence is that MET, like DMT, is primarily used via routes that bypass first-pass metabolism: insufflation and smoking/vaporization. Oral use requires MAOI co-administration (typically harmine or harmaline from Syrian rue), which transforms the experience from a brief flash into a sustained 3-5 hour journey -- but introduces the full spectrum of MAOI combination risks.
Additional Receptor Targets
Like other DMT analogs, MET likely interacts with sigma-1 receptors, which may contribute to the altered-reality quality shared across the tryptamine family. Trace amine-associated receptors (TAARs) are another proposed target for DMT-class molecules, though MET's specific TAAR affinity has not been characterized. The full receptor binding profile remains unpublished.
Pharmacokinetics
Smoked/vaporized: onset within seconds, peak at 5-15 minutes, total duration 15-45 minutes. Insufflated: onset 5-15 minutes, peak at 30-60 minutes, duration 1-3 hours. Oral with MAOI: onset 30-60 minutes, peak at 1.5-2.5 hours, duration 3-5 hours. Oral without MAOI: minimal to absent effects at reasonable doses. Metabolism proceeds via N-dealkylation by CYP450 enzymes and MAO oxidation, ultimately yielding tryptamine metabolites. No formal human pharmacokinetic study exists.
Tolerance
Rapid functional tolerance within 24-48 hours. Complete cross-tolerance with DMT, psilocybin, LSD, and other 5-HT2A agonist psychedelics. Tolerance resets within approximately 7-14 days.
Detection Methods
Urine Detection
MET is not targeted by standard immunoassay-based urine drug screens. As a tryptamine, it is metabolized through monoamine oxidase pathways and produces hydroxylated and deaminated metabolites that are excreted renally. Specialized LC-MS/MS methods can detect tryptamine metabolites in urine for approximately 24 to 48 hours after ingestion. The short duration of action of most base tryptamines results in a relatively brief detection window compared to longer-acting psychoactive substances.
Blood and Serum Detection
Blood detection windows for MET are short, typically 4 to 12 hours after oral administration. If smoked or insufflated, peak concentrations occur within minutes and clearance is more rapid. LC-MS/MS is required for reliable blood detection at the low concentrations characteristic of tryptamine compounds. The rapid metabolism by MAO-A significantly limits the time window in which blood sampling can capture meaningful concentrations.
Standard Drug Panel Inclusion
MET is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. Tryptamines do not cross-react with immunoassay targets for amphetamines, cannabinoids, cocaine metabolites, opiates, PCP, or any other standard panel analyte. Detection requires specific testing at a reference laboratory capable of novel psychoactive substance analysis. Even extended clinical panels rarely include base tryptamines.
Confirmatory Methods
Confirmatory identification of MET relies on LC-MS/MS or GC-MS with appropriate reference standards. GC-MS analysis of tryptamines may require derivatization for optimal sensitivity and chromatographic performance. Reference laboratories specializing in novel psychoactive substances provide the most comprehensive detection capabilities. Standard clinical toxicology laboratories generally do not maintain validated methods for base tryptamines.
Reagent Testing (Harm Reduction)
The Ehrlich reagent produces a purple to violet reaction with MET, confirming the presence of an indole ring system. This is the primary field identification tool and should be used as the first screening test. The Hofmann reagent provides a confirmatory blue to purple reaction. The Marquis reagent typically shows no reaction or a slight brown-yellow discoloration with base tryptamines. A positive Ehrlich result confirms the tryptamine class but does not identify the specific compound. Multiple reagents should be used together for greater confidence in identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 2-Aminoindane | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FEA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2,5-DMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1B-LSD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-AL-LAD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-LSD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-MiPLA | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Shulgin and TiHKAL (1997)
MET was synthesized and documented by Alexander Shulgin as part of his systematic exploration of the N-alkyl tryptamine series in TiHKAL: The Continuation (1997). Shulgin placed MET in its logical structural position between DMT (N,N-dimethyl) and DET (N,N-diethyl), noting its psychoactive properties and providing the synthesis route that would later enable research chemical production. Among the dozens of compounds cataloged in TiHKAL, MET did not receive particular emphasis -- it was one data point in a structure-activity matrix, not a standout finding. The asymmetric N-methyl-N-ethyl substitution was interesting primarily for what it revealed about the pharmacological consequences of incremental alkyl chain lengthening.
Research Chemical Market (2000s-2010s)
MET entered the online research chemical market during the 2000s as vendors began systematically producing compounds from Shulgin's published syntheses. It was always a secondary offering, overshadowed by DMT (which had decades of cultural capital), DPT (which had its clinical history and religious association), and 4-substituted tryptamines like 4-AcO-DMT (which could be marketed as psilocybin analogs). MET found its audience not through notoriety but through word of mouth: users who tried it discovered a short-acting psychedelic with genuine visual depth and a manageable character, and recommended it to others looking for something less overwhelming than DMT.
Community Documentation (2010s-Present)
MET has accumulated modest but genuine community documentation on Reddit, Erowid, and harm reduction platforms. The discussions tend toward the practical: dosing guidelines, route comparisons, experience reports that describe effects with specificity rather than mysticism. This reflects MET's position as a "working" psychedelic -- a tool that people use and discuss without the cultural baggage that surrounds more famous molecules. The community treats MET less as an object of fascination and more as a reliable compound in the tryptamine toolkit.
Legal Status
MET is not explicitly scheduled in most jurisdictions as of 2026. In the United States, it falls under the Federal Analogue Act as a structural analog of DMT, making it potentially illegal when intended for human consumption. It is explicitly controlled in some countries including the United Kingdom (under the Psychoactive Substances Act 2016). The legal landscape varies by jurisdiction and continues to evolve.
Harm Reduction
Test Your Substance
Ehrlich reagent should produce purple to violet, confirming the indole tryptamine structure. MET circulates in the research chemical market where mislabeling and contamination are ongoing concerns. Never assume a powder is what the label says without testing.
Dosing by Route
- Smoked/vaporized: Threshold 5-10 mg | Light 10-20 mg | Common 20-40 mg | Strong 40-60+ mg
- Insufflated: Threshold 15-25 mg | Light 25-50 mg | Common 50-80 mg | Strong 80-120+ mg
- Oral (with MAOI only): Common range 50-100 mg, but MAOI dosing introduces significant additional variables
- A milligram-accurate scale is essential. Do not eyeball doses of any powder-form tryptamine
- Start at the low end of the common range for your chosen route. Individual sensitivity varies
Oral Use Requires MAOI: Understand the Risks
MET is essentially inactive orally without MAO inhibition. If combining with harmalas (Syrian rue, harmine, harmaline), you are introducing the full spectrum of MAOI interaction risks:
- Mandatory dietary restrictions (tyramine-containing foods) for 12-24 hours
- Serotonin syndrome risk if combining with SSRIs, SNRIs, tramadol, or other serotonergic drugs
- Substantially altered dose-response relationship -- start at 50% of your expected dose
- Extended duration (3-5 hours vs. 15-45 minutes smoked) requires different preparation
Do Not Redose Prematurely
When insufflated, onset takes 5-15 minutes and peak effects may not fully manifest for 30 minutes. The temptation to redose after 10 minutes because "it is not strong enough" is the most common path to an unexpectedly intense experience. Wait at least 45 minutes before considering redosing via insufflation.
The Gentleness Is Relative
MET is frequently described as mild or gentle by comparison to DMT. This is accurate but can be misleading. At strong doses (40+ mg smoked, 80+ mg insufflated), MET produces full psychedelic effects including significant perceptual distortion, cognitive alteration, and emotional intensity. "Gentler than DMT" is not the same as "gentle." Treat it with the same respect as any psychedelic.
When Things Get Difficult
Change the environment, change the music, provide calm verbal reassurance. The short duration of smoked MET means that acute distress typically resolves within 20-30 minutes. Benzodiazepines (diazepam 10-20 mg) are effective if needed but are rarely necessary given the brief timeline. For insufflated or MAOI-extended experiences, standard psychedelic crisis management applies.
Toxicity & Safety
Acute Physical Toxicity
No formal human toxicological data exists for MET. Safety assessment relies on class membership (DMT analog with the same primary mechanism of action) and community experience accumulated over approximately two decades of use without reports of serious physiological harm attributable to MET's pharmacological action. The acute toxicity profile is presumed to mirror that of other classical tryptamine psychedelics: very low at standard doses, with a wide therapeutic index.
Physiological Effects
Mild sympathomimetic stimulation at standard doses: pupil dilation, heart rate elevation (10-30 bpm), mild blood pressure increase, possible nausea during onset. The cardiovascular effects are transient and well-tolerated in healthy individuals. Insufflation causes nasal irritation and possible mucosal damage with frequent use. Smoking introduces standard combustion-related respiratory exposure.
Nausea
Onset nausea is reported but appears less prominent with MET than with some other tryptamines, particularly when smoked or vaporized. Insufflated doses can trigger nausea from drip. Oral use with MAOI commonly produces nausea from the MAOI component itself.
MAOI Combination Risks
Oral MET use requires MAOI co-administration, which introduces the most significant physical risk:
- Serotonin syndrome -- Combining MAOIs with serotonergic tryptamines creates risk of a potentially life-threatening condition characterized by hyperthermia, muscle rigidity, autonomic instability, and altered mental status
- Tyramine interactions -- MAOIs require dietary restrictions; tyramine-rich foods (aged cheese, cured meats, fermented products) can trigger hypertensive crisis
- Drug interactions -- Absolute contraindication for concurrent use of SSRIs, SNRIs, tramadol, dextromethorphan, and other serotonergic medications
Psychological Risks
- Acute anxiety -- Possible at higher doses, particularly with rapid onset via smoking. MET's relatively mild headspace makes severe psychological distress less common than with DMT or DPT, but it is not absent
- Psychosis risk -- Standard absolute contraindication for individuals with personal or family history of schizophrenia, schizoaffective disorder, or bipolar I disorder
- HPPD -- Possible, as with all 5-HT2A agonist psychedelics, though no MET-specific data exists
- Dose-dependent intensity -- At strong doses, MET can produce significant ego softening and emotional intensity that may be difficult for unprepared users
Drug Interactions
- MAOIs (harmalas, pharmaceutical) -- Required for oral activity but introduces serotonin syndrome risk; demands expertise and dietary precautions
- Lithium -- Absolute contraindication; seizure risk with serotonergic psychedelics
- Cannabis -- Unpredictable intensity amplification
- Stimulants -- Increased cardiovascular and psychological stress
- SSRIs/SNRIs -- Reduced effects; dangerous in combination with MAOIs
Addiction Potential
MET has no meaningful addiction potential. It produces no physical dependence, no withdrawal syndrome, and no compulsive drug-seeking behavior. Rapid tolerance develops within 24-48 hours, and complete cross-tolerance exists with DMT, psilocybin, LSD, mescaline, and all other 5-HT2A agonist psychedelics, preventing both daily use and substitution patterns. Tolerance resets within approximately 7-14 days. Classical psychedelics as a class rank at the bottom of addiction liability rankings across all drug categories -- they are the opposite of addictive in that repeated use in short succession produces diminishing returns rather than escalating desire. MET's short duration and relatively gentle character make it theoretically more amenable to frequent use than longer-acting psychedelics, but the pharmacological tolerance mechanism renders this moot: using it again the next day would produce substantially weaker effects. A small number of individuals may develop a pattern of habitual psychedelic use as a coping mechanism or form of escapism, but this is uncommon with MET specifically and is fundamentally different from the neurochemical compulsion that characterizes true substance addiction.
Overdose Information
Can You Fatally Overdose on MET?
Fatal overdose from MET's pharmacological action alone is extremely unlikely. No deaths attributable to MET toxicity have been documented. The therapeutic index for classical tryptamine psychedelics is very wide, and MET's pharmacological profile offers no reason to expect it to be an exception.
Recognizing a Problem
MET's relatively gentle character means that medical emergencies are rare, but they are not impossible -- particularly at high doses, with MAOI combinations, or in predisposed individuals.
Watch for:
- Severe anxiety or panic that persists beyond 30 minutes (for smoked route) or does not respond to reassurance
- Signs of serotonin syndrome (critical if MAOIs are involved): muscle rigidity, rapidly rising body temperature, agitation, tremor, rapid heart rate, confusion
- Seizures -- rare but an absolute indication for emergency medical care
- Loss of consciousness or complete unresponsiveness
- Hypertensive crisis (if MAOIs and tyramine-containing foods are involved): severe headache, chest pain, vision changes
What to Do
For psychological distress during a smoked MET experience: the most effective intervention is often simply waiting. The acute effects typically resolve within 20-30 minutes. Calm verbal reassurance, a change of environment, and a reminder that the experience is temporary and safe are usually sufficient. Benzodiazepines are effective but rarely necessary for smoked MET's short duration.
For insufflated or MAOI-extended experiences: standard psychedelic crisis management applies. Move to a calm, quiet environment. Provide concrete reassurance: "You took MET. You are safe. This will pass." Benzodiazepines (diazepam 10-20 mg) if the person is conscious and able to swallow.
For medical emergencies: call emergency services immediately for seizures, dangerously elevated body temperature, signs of serotonin syndrome, hypertensive crisis symptoms, loss of consciousness, or self-harm behavior. Good Samaritan laws protect callers in many jurisdictions. Treatment is supportive; there is no specific MET antidote.
Tolerance
| Full | Develops almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
Due to its relative obscurity, the possession and sale of MET is unscheduled in most countries.
Germany: MET is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan: MET is a controlled substance in Japan as of March 20, 2023.
New Zealand: MET is an analogue of DMT, so is a Class C controlled substance in New Zealand.
Switzerland: MET is not controlled under Buchstabe A, B, C and D. It could be considered legal.
United Kingdom: MET is a Class A controlled substance in the UK under a generic clause originally added in 1977 that covers derivatives of tryptamine that are modified by alkyl substitution at the nitrogen atom of the tryptamine side chain.
United States: MET is unscheduled in the United States. However, it is likely that it would be considered a controlled substance analogue of DMT or DET, in which case, sales for human consumption or possession with the intent to ingest could be prosecuted under the Federal Analogue Act.
Responsible use
Research chemical
Psychedelic
Tryptamine
DMT
MET (Wikipedia)
MET (Erowid Vault)
MET (Isomer Design)
Discussion
The Big & Dandy MET Thread (Bluelight)
Experience Reports (4)
Tips (10)
Use a milligram scale to weigh MET if it comes as a powder. Eyeballing doses of potent psychedelics is irresponsible. A quality 0.001g scale costs under $30 and could prevent a seriously overwhelming experience.
Do not combine MET with lithium (seizure risk), tramadol (seizure/serotonin syndrome risk), or cannabis at higher doses unless very experienced. Cannabis dramatically intensifies and can destabilize a psychedelic experience.
Set and setting are paramount with MET. Choose a familiar, comfortable environment where you feel safe. Have trusted company or a trip sitter, especially for your first experience. Avoid stressful locations or social obligations.
4-substituted tryptamines like 4-HO-MET are fragile and degrade with heat and in liquid solutions including propylene glycol. If making gummies or solutions, minimize heat exposure time and store frozen. Degradation means unreliable dosing which is a real safety concern.
MET fumarate salt may be orally active around 80-110mg, though reports are inconsistent. Freebase is reliably active when vaporized at 15-20mg. If you have the fumarate form and want to try oral dosing, start very low and titrate up across separate sessions.
The freebase form of MET is the waxy or oily form suitable for vaporization, while the fumarate salt is a stable powder better for storage and potentially oral use. Converting between forms is possible but not trivial. Know which form you have before deciding on your route of administration.
Community Discussions (12)
See Also
Similar by Effects
Same Class
References (5)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- PubChem: MET
PubChem compound page for MET (CID: 6137)
pubchem - MET - TripSit Factsheet
TripSit factsheet for MET
tripsit - MET - Wikipedia
Wikipedia article on MET
wikipedia